LATEST ADVANCE IN RENAL TRANSPLANT TO IMPROVE REJECTION AND COMPLICATIONS OF IMMUNOSUPPRESSION
The IMMUNOBIOGRAM® (IMBG) is a unique In Vitro Diagnostic (IVD) immunoassay offers a personalized comparative evaluation of the patient´s sensitivity/resistance profile to a panel of the most commonly used immunosuppressive drugs (IS) in clinical practice.
The IMMUNOBIOGRAM® is a combination of a biotechnological KIT, and a software to produce meaningful results and elaborate reports. There is no other product providing similar information.
The IMMUNOBIOGRAM® allows physicians to predict and monitor the response of patients‘ immune system cells to a specific IS. These cells are the target of all approved immunosuppressant therapies and are linked to drug efficacy.
The IMMUNOBIOGRAM® was funded from the European Union’s Horizon 2020 research and innovation program.
“With this product the Beneficiary will revolutionize kidney transplantation market and will become a key player in this system.”
(2018 European Commission Report)
The IMBG has been studied in more than 250 patients (national and international studies, 11 centers, 5 countries (Europe & USA)), showing very positive results that have been presented in major international transplantation congresses. Also, pharmacoeconomic data shows that the use of the IMBG would entail significant savings to the Health Care systems.
The test has been clinically tested in patients after more than one year of the transplant. It can be used to identify and monitor patients at risk of rejection (who might require an increase of immunosuppression or a change in the immunosuppressive regime prescribed), and in patients with low risk to profit from a gradual reduction of immunosuppression and avoidance of severe side effects
The IMMUNOBIOGRAM® will be available in the European market in 2022 and in North America in 2023.